Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
JAGX 
Jaguar Animal Health Inc (JAGX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/11/2025: JAGX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -71.54% | Avg. Invested days 21 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/11/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 2.87M USD | Price to earnings Ratio - | 1Y Target Price 150 |
Price to earnings Ratio - | 1Y Target Price 150 | ||
Volume (30-day avg) 336389 | Beta 0.81 | 52 Weeks Range 4.02 - 540.00 | Updated Date 04/7/2025 |
52 Weeks Range 4.02 - 540.00 | Updated Date 04/7/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -130.69 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-03-31 | When Before Market | Estimate -18.5 | Actual -125.8 |
Profitability
Profit Margin - | Operating Margin (TTM) -232.46% |
Management Effectiveness
Return on Assets (TTM) -36.99% | Return on Equity (TTM) -565.74% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 31358291 | Price to Sales(TTM) 0.25 |
Enterprise Value 31358291 | Price to Sales(TTM) 0.25 | ||
Enterprise Value to Revenue 2.68 | Enterprise Value to EBITDA -0.63 | Shares Outstanding 656086 | Shares Floating 548543 |
Shares Outstanding 656086 | Shares Floating 548543 | ||
Percent Insiders 14.89 | Percent Institutions 1.72 |
Analyst Ratings
Rating 5 | Target Price 6 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Jaguar Animal Health Inc
Company Overview
History and Background
Jaguar Animal Health, Inc. (now known as Napo Pharmaceuticals, Inc.) was focused on developing and commercializing gastrointestinal products for animals. It was founded to address unmet needs in animal health, focusing on sustainably derived ingredients.
Core Business Areas
- Animal Health: Development and commercialization of prescription products for companion and production animals with gastrointestinal disorders.
Leadership and Structure
Information on Jaguar Animal Health's specific leadership team and organizational structure is limited in publicly available current data. The company has undergone significant changes, including renaming and shifting its focus.
Top Products and Market Share
Key Offerings
- Canalevia: A prescription drug approved for the treatment of chemotherapy-induced diarrhea (CID) in dogs. Market share data is unavailable due to the company's current status. Competitors would include traditional anti-diarrheal medications and supportive care therapies offered by companies like Zoetis (ZTS) and Elanco Animal Health (ELAN).
- Neonorm Calf: A product aimed at managing diarrhea in newborn calves. Market share data is unavailable due to the company's current status. Competitors include companies offering bovine health products, such as Boehringer Ingelheim and Merck Animal Health (MRK).
Market Dynamics
Industry Overview
The animal health industry is characterized by increasing pet ownership and a growing demand for advanced veterinary care and pharmaceuticals. The market is competitive, with several large players.
Positioning
Given the shift to Napo Pharmaceuticals, Jaguar Animal Health's former positioning as a GI-focused animal health company is no longer relevant. Its competitive advantages previously included sustainably derived ingredients and targeted treatments.
Total Addressable Market (TAM)
The global animal health market is estimated to be over $50 billion. Jaguar Animal Health, when focused on animal health, aimed to capture a share of the gastrointestinal segment, a subset of this larger TAM. However, based on their current status they are not positioned within this TAM anymore.
Upturn SWOT Analysis
Strengths
- Proprietary formulations
- Sustainability focus
- Potential for targeted therapies
Weaknesses
- Limited financial resources
- Small market share prior to name change
- Dependence on a small number of products
Opportunities
- Partnerships with larger animal health companies
- Expansion into new geographic markets
- Development of new products for unmet needs
Threats
- Competition from established players
- Regulatory hurdles
- Pricing pressure
Competitors and Market Share
Key Competitors
- ZTS
- ELAN
- MRK
Competitive Landscape
Prior to the shift, Jaguar Animal Health was a smaller player competing with established animal health giants. Its unique selling proposition was its focus on natural ingredients.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth was limited by financial constraints and competition.
Future Projections: Future projections are related to Napo Pharmaceuticals and its human health focus.
Recent Initiatives: The most significant recent initiative was the transition to Napo Pharmaceuticals, focusing on human health.
Summary
Jaguar Animal Health Inc, now Napo Pharmaceuticals, shifted its focus from animal to human health. Previously focused on GI products for animals, it faced challenges in a competitive market. Its success depended on strategic partnerships and innovation, but currently, its prospects are tied to its new focus as Napo.
Similar Companies
ELAN
Elanco Animal Health
ELAN
Elanco Animal Health
MRK
Merck & Company Inc
MRK
Merck & Company Inc
ZTS
Zoetis Inc
ZTS
Zoetis Inc
Sources and Disclaimers
Data Sources:
- Company press releases
- SEC filings
- Industry reports
Disclaimers:
This analysis is based on publicly available information and historical data. The information provided is not financial advice, and the user should seek professional guidance before making investment decisions. The company's transition to Napo Pharmaceuticals significantly alters its business profile, making historical data less relevant.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Jaguar Animal Health Inc
Exchange NASDAQ | Headquaters San Francisco, CA, United States | ||
IPO Launch date 2015-05-13 | Founder, CEO, President & Director Ms. Lisa A. Conte | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://jaguar.health |
Full time employees - | Website https://jaguar.health | ||
Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company's products include Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing NP-300, a second-generation antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.